Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Otsuka to Buy Neurovance, Gets Its Hands on Non-Stimulant ADHD Med
March 6, 2017
- Bioverativ Japan Now Up and Running, Set to Keep Double-Digit Growth: President
March 3, 2017
- NCC, Daiichi Sankyo Begin PI on Mutant IDH1 Inhibitor for Glioma
March 2, 2017
- Fujifilm Creates Bio CDMO Division, Aims for 100 Billion Yen Sales in FY2023
March 2, 2017
- GSK Remains Strong Player in Respiratory, Japan Sales Slip 1.7%: Fauchet
March 1, 2017
- Nobelpharma Forms Preparatory Office for Overseas Biz
March 1, 2017
- ASKA Gets Asian Rights to Pieris’ Anemia Med
March 1, 2017
- Astellas, Affinivax Ink Global Partnership on Pneumococcal Vaccine
March 1, 2017
- Novo Files Once-Weekly GLP-1 in Japan
March 1, 2017
- Tolero Aims to File for AML Treatment Alvocidib in FY2018 in US: Sumitomo Dainippon
March 1, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
- Kyowa Earns Rights for Astellas’ Extended-Release Quetiapine
February 28, 2017
- Shionogi to Comarket Methapain with Terumo
February 28, 2017
- Alecensa Gets Approval in Taiwan: Chugai
February 28, 2017
- Sanofi Files Atopic Dermatitis Treatment Dupilumab in Japan
February 28, 2017
- LEO Pharma Applies for Gel Formulation for Dovobet
February 28, 2017
- Daiichi Sankyo to Set Up Brand Strategy Unit to Spur Cancer Biz
February 27, 2017
- Eisai’s Yuji Matsue to Spearhead EA Pharma
February 27, 2017
- Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
February 27, 2017
- Koichi Shimada to Lead Alfresa Pharma
February 24, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…